Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

"Day Preparative Regimen for GVHD Prophylaxis~* 7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 3 Fludarabine 30 mg/m(2)IV~* 2 REST Tacrolimus 0.01 mg/kg CIVI~* 1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~ * 1 Methotrexate 5mg/m(2)IV~ * 3 Methotrexate 5mg/m(2)IV~ * 6 Methotrexate 5mg/m(2)IV~ * 7 G-CSF 5mcg/kg SQ daily~ * 11 Methotrexate 5mg/m(2)IV~ * 90 Evaluate Response"